Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Shanghai
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Tasly Pharmaceutical Group Co Ltd

+ Add to Watchlist

600535:CH

44.070 CNY 0.030 0.07%

As of 22:12:36 ET on 03/02/2015.

Snapshot for Tasly Pharmaceutical Group Co Ltd (600535)

Open: 43.900 Day's Range: 43.500 - 44.460 Volume: 4,466,552
Previous Close: 44.100 52wk Range: 35.350 - 46.860 1-Yr Rtn: +1.74%

Stock Chart for 600535

No chart data available.
  • 600535:CH 44.060
  • 1D
  • 1M
  • 1Y
44.100
Interactive 600535 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 600535

Current P/E Ratio (ttm) 34.1492
Estimated P/E(12/2014) 31.8182
Relative P/E vs. SHASHR 2.1278
Earnings Per Share (CNY) (ttm) 1.2914
Est. EPS (CNY) (12/2014) 1.3860
Est. PEG Ratio -
Market Cap (M CNY) 45,548.36
Shares Outstanding (M) 1,032.84
30 Day Average Volume 8,772,792
Price/Book (mrq) 9.8855
Price/Sale (ttm) 3.7562
Dividend Indicated Gross Yield 0.79%
Cash Dividend (CNY) 0.3500
Dividend Ex-Date 06/19/2014
5 Year Dividend Growth 11.84%
Next Earnings Announcement 03/30/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 600535

  • Revenue
  • Net Income (M/CNY)
  • Profit Margin (%)

Company Profile & Key Executives for 600535

Tasly Pharmaceutical Group Co researches, produces, and sells Chinese medicines which are mainly derived from the root of red-rooted salvia. The Company's products focus on the treatment of cardiovascular and brain blood vessel diseases.

Yan XijunChairmanZhu YonghongVice Chairman
Kaijing YanPresidentJinyong CaiVice President
More Company Profile & Key Executives for 600535

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil